Skip to main content

Table 1 IMP-characteristics of Envarsus®

From: EnGraft: a multicentre, open-label, randomised, two-arm, superiority study protocol to assess bioavailability and practicability of Envarsus® versus Advagraf™ in liver transplant recipients

IMP name

Envarsus®

Active ingredient

Tacrolimus monohydrate

Pharmaceutical form

Prolonged-release tablet

Presentation

Oval, white to off-white uncoated tablet

Administration

Once daily, oral formulation provided in 0.75 mg, 1.0 mg and 4.0 mg dosage strengths